Ajinomoto Group Ventures is the corporate venture capital arm of Ajinomoto Co., Inc., a $10B revenue technology leader in amino science. It invests in global transformative startups across healthcare, biotech & life sciences, food & agriculture, and climate & energy, leveraging Ajinomoto Group resources to drive impact.
Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-a (56% of deals). Average disclosed round size is $60.3M (across 5 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| RRestore Vision Inc. | Series A | — | Jan 2026 |
 Mixx Technologies | Series A | $33M | Dec 2025 |
 Somite | Series A | $47M | May 2025 |
 Safire Technology Group, Inc. | Unknown | — | Sep 2024 |
| AAscend Advanced Therapies | Series A | $132.5M | Mar 2023 |
 Tsubame BHB | Series C | — | Jul 2022 |
 MycoTechnology | Series B | $42M | Oct 2017 |
 Cellular Intelligence | Series A | $47M | — |
 Restore Vision | Series B | — | — |
Top Co-Investors
Harpoon Ventures2 shared
Chan Zuckerberg Initiative2 shared
Fusion Fund2 shared
SciFi VC2 shared
Khosla Ventures2 shared
TechAviv2 shared
ANRI2 shared
Astellas Venture Management2 shared
JIC Venture Growth Investments2 shared
Hoxton Ventures1 shared
AMD Ventures1 shared
Pitango VC1 shared
Lerer Hippeau1 shared
CapitalG1 shared
Systemiq Capital1 shared
TDK Ventures1 shared
ICM HPQC Fund1 shared
4BIO Capital1 shared
DCVC1 shared
Petrichor Capital Partners1 shared
Last updated: 9 September 2026